Gilead Sciences Stock Debt To Equity
| GILD34 Stock | BRL 287.56 4.47 1.58% |
Gilead Sciences fundamentals help investors to digest information that contributes to Gilead Sciences' financial success or failures. It also enables traders to predict the movement of Gilead Stock. The fundamental analysis module provides a way to measure Gilead Sciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Gilead Sciences stock.
Gilead |
Gilead Sciences Company Debt To Equity Analysis
Gilead Sciences' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Gilead Sciences Debt To Equity | 117.00 % |
Most of Gilead Sciences' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Gilead Sciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
According to the company disclosure, Gilead Sciences has a Debt To Equity of 117%. This is 118.53% higher than that of the Healthcare sector and 6.97% higher than that of the Drug Manufacturers - Major industry. The debt to equity for all Brazil stocks is 140.25% lower than that of the firm.
Gilead Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Gilead Sciences' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Gilead Sciences could also be used in its relative valuation, which is a method of valuing Gilead Sciences by comparing valuation metrics of similar companies.Gilead Sciences is rated # 2 in debt to equity category among its peers.
Gilead Fundamentals
| Return On Equity | 0.22 | |||
| Return On Asset | 0.1 | |||
| Profit Margin | 0.17 % | |||
| Operating Margin | 0.40 % | |||
| Current Valuation | 686.18 B | |||
| Shares Outstanding | 2.49 B | |||
| Price To Earning | 28.35 X | |||
| Price To Book | 5.30 X | |||
| Price To Sales | 21.27 X | |||
| Revenue | 27.28 B | |||
| Gross Profit | 21.62 B | |||
| EBITDA | 6.75 B | |||
| Net Income | 4.59 B | |||
| Cash And Equivalents | 28.36 B | |||
| Cash Per Share | 22.39 X | |||
| Total Debt | 25.18 B | |||
| Debt To Equity | 117.00 % | |||
| Current Ratio | 3.76 X | |||
| Book Value Per Share | 17.01 X | |||
| Cash Flow From Operations | 9.07 B | |||
| Earnings Per Share | 9.63 X | |||
| Price To Earnings To Growth | 0.71 X | |||
| Number Of Employees | 31 | |||
| Beta | 0.41 | |||
| Market Capitalization | 572.2 B | |||
| Total Asset | 63.17 B | |||
| Z Score | 13.2 | |||
| Annual Yield | 0.03 % | |||
| Net Asset | 63.17 B | |||
| Last Dividend Paid | 2.92 |
About Gilead Sciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Gilead Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Gilead Sciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Gilead Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Gilead Stock
When determining whether Gilead Sciences is a strong investment it is important to analyze Gilead Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gilead Sciences' future performance. For an informed investment choice regarding Gilead Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.